Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $1.61 billion. The enterprise value is $1.15 billion.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 342.83 million shares outstanding. The number of shares has increased by 27.08% in one year.
| Current Share Class | 341.83M |
| Shares Outstanding | 342.83M |
| Shares Change (YoY) | +27.08% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 24.69% |
| Owned by Institutions (%) | 54.20% |
| Float | 232.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.62 |
| Forward PS | 8.42 |
| PB Ratio | 5.33 |
| P/TBV Ratio | 5.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.95, with a Debt / Equity ratio of 0.22.
| Current Ratio | 6.95 |
| Quick Ratio | 6.67 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.57 |
Financial Efficiency
Return on equity (ROE) is -53.18% and return on invested capital (ROIC) is -31.50%.
| Return on Equity (ROE) | -53.18% |
| Return on Assets (ROA) | -23.46% |
| Return on Invested Capital (ROIC) | -31.50% |
| Return on Capital Employed (ROCE) | -41.57% |
| Weighted Average Cost of Capital (WACC) | 13.23% |
| Revenue Per Employee | $211,081 |
| Profits Per Employee | -$686,668 |
| Employee Count | 298 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +136.18% in the last 52 weeks. The beta is 1.61, so Nuvation Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | +136.18% |
| 50-Day Moving Average | 4.97 |
| 200-Day Moving Average | 4.76 |
| Relative Strength Index (RSI) | 52.29 |
| Average Volume (20 Days) | 3,286,529 |
Short Selling Information
The latest short interest is 48.73 million, so 14.22% of the outstanding shares have been sold short.
| Short Interest | 48.73M |
| Short Previous Month | 46.86M |
| Short % of Shares Out | 14.22% |
| Short % of Float | 20.98% |
| Short Ratio (days to cover) | 9.62 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $62.90 million and -$204.63 million in losses. Loss per share was -$0.60.
| Revenue | 62.90M |
| Gross Profit | 53.60M |
| Operating Income | -213.06M |
| Pretax Income | -204.63M |
| Net Income | -204.63M |
| EBITDA | -211.33M |
| EBIT | -213.06M |
| Loss Per Share | -$0.60 |
Full Income StatementBalance Sheet
The company has $529.21 million in cash and $66.94 million in debt, with a net cash position of $462.27 million or $1.35 per share.
| Cash & Cash Equivalents | 529.21M |
| Total Debt | 66.94M |
| Net Cash | 462.27M |
| Net Cash Per Share | $1.35 |
| Equity (Book Value) | 305.72M |
| Book Value Per Share | 0.88 |
| Working Capital | 489.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$173.43 million and capital expenditures -$354,000, giving a free cash flow of -$173.78 million.
| Operating Cash Flow | -173.43M |
| Capital Expenditures | -354,000 |
| Depreciation & Amortization | 1.74M |
| Net Borrowing | 197.71M |
| Free Cash Flow | -173.78M |
| FCF Per Share | -$0.51 |
Full Cash Flow StatementMargins
| Gross Margin | 85.22% |
| Operating Margin | -338.72% |
| Pretax Margin | -325.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.08% |
| Shareholder Yield | -27.08% |
| Earnings Yield | -12.70% |
| FCF Yield | -10.79% |
Analyst Forecast
The average price target for Nuvation Bio is $11.38, which is 142.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.38 |
| Price Target Difference | 142.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 64.94% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nuvation Bio has an Altman Z-Score of -0.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.35 |
| Piotroski F-Score | 3 |
